EMEA-000828-PIP01-09-M09

Table of contents

Key facts

Invented name
Jardiance
Active substance
empagliflozin
Therapeutic area
Endocrinology-Gynaecology-Fertility-Metabolism
Decision number
P/0283/2021
PIP number
EMEA-000828-PIP01-09-M09
Pharmaceutical form(s)
Film-coated tablet
Condition(s) / indication(s)
Treatment of type II diabetes mellitus
Route(s) of administration
Oral use
Contact for public enquiries
Boehringer Ingelheim International GmbH

E-mail: COMMSPaediatrics@boehringer-ingelheim.com
Tel: +49 (0)6132 77 8271

Decision type
PM: decision on the application for modification of an agreed PIP
Compliance procedure number
EMEA-C-000828-PIP01-09-M09
Compliance opinion date
16/12/2022
Compliance outcome
positive

Decision

Related content

How useful was this page?

Add your rating
Average
1 rating